Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
|Articles|October 22, 2021
Daily OTC Pearl: Simethicone (Gas-X)
Author(s)Saro Arakelians, PharmD
Simethicone is an anti-foaming agent that is taken orally to help reduce the buildup of intestinal and stomach gases that cause bloating and discomfort.
Advertisement
OTC/Lifestyle Pearl of the Day: Simethicone (Gas-X)
Indication: Gas-X works with your body to help relieve gas.
Insight:
- Simethicone is the active ingredient in Gas-X.
- It’s an anti-foaming agent that is taken orally to help reduce the buildup of intestinal and stomach gases that cause bloating and discomfort.
- Dose ranges from 125 mg to 250 mg and taken in 2 to 4 tablets per day.
- Dosage forms: Gas-x comes in tablet, capsule, tablet-chewable, liquid, oral suspension, and strips of oral distinguishing format
- Adverse effects include rash, itching, swelling, severe dizziness and trouble breathing.
Sources:
Advertisement
Related to this article
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
4
Building a BCMA Bispecific Around the Patient Experience, Not Just the Molecule
5